New hope for dravet syndrome: phase 3 trial of LP352 aims to cut seizure frequency
Disease control
Recruiting now
This study tests whether the drug LP352 can safely reduce seizures in children and adults with Dravet syndrome, a severe form of epilepsy. About 160 participants will receive either LP352 or a placebo, and researchers will track changes in seizure frequency over several months. T…
Phase: PHASE3 • Sponsor: Longboard Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC